Penn Researchers Find GPNMB Antibodies May Slow Early Parkinson's Progression
Updated
Updated · geneonline · May 12
Penn Researchers Find GPNMB Antibodies May Slow Early Parkinson's Progression
2 articles · Updated · geneonline · May 12
University of Pennsylvania researchers identified GPNMB as a potential drug target that could slow progression in early-stage Parkinson's disease.
Monoclonal antibodies aimed at GPNMB appeared to inhibit a key immune-associated protein implicated in the disease process, pointing to an immune-based treatment strategy.
The findings suggest intervention may be most useful in Parkinson's early stages, when modifying disease-driving immune activity could help delay worsening.
If validated in further studies, the approach could open a new therapeutic avenue beyond symptom management for Parkinson's patients.
A rival drug is in late-stage trials. Can this new antibody win the race to halt Parkinson's progression?
This brain protein was once seen as protective. Why is blocking it now the new hope for Parkinson's?
A promising Parkinson's therapy has been found. But can it overcome the brain's near-impenetrable security wall?